Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of -14.10% is 92% below its 5-year average of -7.34%, around the middle of its 5-year range (-35.46%–13.19%).
17.56% above its 12-month average of -17.10%.
Reported quarterly EBITDA margin; no daily interpolation. Q2 FY2026 (2026-06-30): -17.48%.
EBITDA MARGIN
-14.10%
EBITDA MARGIN AVG TTM
-17.10%
EBITDA MARGIN AVG 3Y
-12.17%
EBITDA MARGIN AVG 5Y
-7.34%
EBITDA MARGIN AVG 10Y
N/A
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+17.56%
CURRENT VS 3Y AVG
-15.90%
CURRENT VS 5Y AVG
-92.00%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Cytek Biosciences, Inc.
Market Cap
$786.48M
EBITDA Margin
-14.10%
TTM Avg
-17.10%
3Y Avg
-12.17%
5Y Avg
-7.34%
Market Cap
$780.95M
EBITDA Margin
18.47%
TTM Avg
18.88%
3Y Avg
13.21%
5Y Avg
14.52%
Market Cap
$776.24M
EBITDA Margin
-28.62%
TTM Avg
-126.34%
3Y Avg
-26187.68%
5Y Avg
-23869.36%
Market Cap
$775.72M
EBITDA Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$774.32M
EBITDA Margin
-4915.19%
TTM Avg
-4915.19%
3Y Avg
-4915.19%
5Y Avg
-4915.19%
Market Cap
$767.46M
EBITDA Margin
-123018.64%
TTM Avg
-69257.96%
3Y Avg
-35033.94%
5Y Avg
-23599.85%
Market Cap
$819.44M
EBITDA Margin
12.02%
TTM Avg
14.44%
3Y Avg
-4.83%
5Y Avg
-238.26%
Market Cap
$749.55M
EBITDA Margin
-27116.80%
TTM Avg
-23848.80%
3Y Avg
-16467.00%
5Y Avg
-16467.00%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Cytek Biosciences, Inc. (CTKB) | $786.48M | -14.10% | -17.10% | -12.17% | -7.34% |
| AdaptHealth Corp. (AHCO)vs › | $780.95M | 18.47% | 18.88% | 13.21% | 14.52% |
| Geron Corporation (GERN)vs › | $776.24M | -28.62% | -126.34% | -26187.68% | -23869.36% |
| Design Therapeutics, Inc. (DSGN)vs › | $775.72M | 0.00% | 0.00% | 0.00% | 0.00% |
| Attovia Therapeutics, Inc. (ATTO)vs › | $774.32M | -4915.19% | -4915.19% | -4915.19% | -4915.19% |
| Avalo Therapeutics, Inc. (AVTX)vs › | $767.46M | -123018.64% | -69257.96% | -35033.94% | -23599.85% |
| InMode Ltd. (INMD)vs › | $812.20M | 23.23% | 25.96% | 33.88% | 36.34% |
| Gyre Therapeutics, Inc. (GYRE)vs › | $819.44M | 12.02% | 14.44% | -4.83% | -238.26% |
| Candel Therapeutics, Inc. (CADL)vs › | $749.55M | -27116.80% | -23848.80% | -16467.00% | -16467.00% |
| Ardelyx, Inc. (ARDX)vs › | $837.43M | -9.31% | -8.54% | -46.73% | -472.39% |
Gross Margin
53.2%
EBITDA Margin
-14.1%
Operating Margin
-21.6%
Net Margin
-39.0%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-06-30 | -17.48% |
| 2026-03-31 | -35.46% |
| 2025-12-31 | -4.11% |
| 2025-09-30 | -11.73% |
| 2025-06-30 | -16.74% |
| 2025-03-31 | -29.17% |
| 2024-12-31 | 9.96% |
| 2024-09-30 | -2.79% |
| 2024-06-30 | -12.97% |
| 2024-03-31 | -18.44% |
| 2023-12-31 | 3.93% |
| 2023-09-30 | -8.04% |
| 2023-06-30 | -15.11% |
| 2023-03-31 | -30.09% |
| 2022-12-31 | 4.03% |
| 2022-09-30 | 5.26% |
| 2022-06-30 | -0.06% |
| 2022-03-31 | -2.53% |
| 2021-12-31 | 5.15% |
| 2021-09-30 | 8.98% |
| 2021-06-30 | 13.19% |
| 2021-03-31 | 5.35% |
| 2020-12-31 | 26.24% |
| 2020-09-30 | 27.45% |
| 2020-06-30 | -0.30% |
| 2020-03-31 | -3.36% |
